BCL-2 and PAX2 Expressions in EIN which Had Been Previously Diagnosed as Non-Atypical Hyperplasia.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Frontiers Media S. A Country of Publication: Switzerland NLM ID: 9706087 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-2807 (Electronic) Linking ISSN: 12194956 NLM ISO Abbreviation: Pathol Oncol Res Subsets: MEDLINE
    • Publication Information:
      Publication: 2021- : Lausanne, Switzerland : Frontiers Media S. A.
      Original Publication: Budapest, Hungary : Science Press, c1995-
    • Subject Terms:
      Biomarkers, Tumor/*analysis ; Carcinoma in Situ/*diagnosis ; Endometrial Neoplasms/*diagnosis ; PAX2 Transcription Factor/*biosynthesis ; Proto-Oncogene Proteins c-bcl-2/*biosynthesis; Adult ; Aged ; Carcinoma in Situ/pathology ; Carcinoma, Endometrioid/diagnosis ; Carcinoma, Endometrioid/pathology ; Endometrial Hyperplasia/diagnosis ; Endometrial Hyperplasia/pathology ; Endometrial Neoplasms/pathology ; Female ; Humans ; Middle Aged ; Precancerous Conditions/diagnosis ; Precancerous Conditions/pathology ; Young Adult
    • Abstract:
      The relationship between PAX2 and another anti-apoptotic gene, BCL-2, has been shown in a limited number of studies. The aims of this study are to investigate the value of PAX2 and BCL-2 expressions in lesions which have been defined as nonatypical hyperplasia in terms of detecting EIN and to evaluate the relations of these proteins in EIN. For this purpose, 108 cases of non-atypical endometrial hyperplasia diagnosed from 2006 to 2011 were re-evaluated. Immunohistochemical studies with PAX2 and BCL-2 were performed in 20 cases with EIN and 34 cases with benign hyperplasia. The mean BCL-2 immunohistochemistry scores of benign hyperplasia and EIN cases were 4.06 ± 1.04 and 4.63 ± 2.03, respectively. The mean BCL-2 score of EIN cases was significantly higher than benign hyperplasia (p = 0.021). The mean PAX2 scores of benign hyperplasia and EIN cases were 4.32 ± 1.07 and 2.19 ± 2.34, respectively. The mean PAX2 scores of EIN cases were significantly lower than benign hyperplasia (p = 0.001). BCL-2 expression was increased compared to normal endometrium in 66.7% of EIN cases, and PAX2 expression was decreased in 73.3%. Consistent with this, in 60% of cases, BCL-2 expression was increased compared to normal endometrium, while PAX2 expression was decreased. BCL-2 and PAX2 protein expression changes occur in early phases of endometrial tumorigenesis. These changes are often seen as a simultaneous increase in BCL-2 expression and decrease in PAX2 expression.
    • References:
      Cancer. 1999 Apr 15;85(8):1799-809. (PMID: 10223575)
      J Pathol. 2000 Mar;190(4):462-9. (PMID: 10699996)
      J Clin Pathol. 2002 May;55(5):326-31. (PMID: 11986334)
      Cancer. 2002 Oct 1;95(7):1463-71. (PMID: 12237915)
      Nature. 1992 Oct 8;359(6395):552-4. (PMID: 1406975)
      Mod Pathol. 2005 Mar;18(3):324-30. (PMID: 15529181)
      Cancer. 2005 Jun 1;103(11):2304-12. (PMID: 15856484)
      Nature. 2005 Dec 15;438(7070):981-7. (PMID: 16355216)
      Cell Death Differ. 2006 Aug;13(8):1256-9. (PMID: 16710363)
      J Clin Oncol. 2006 Oct 10;24(29):4783-91. (PMID: 17028294)
      Pathol Res Pract. 2007;203(3):153-62. (PMID: 17317031)
      Int J Cancer. 2008 Dec 15;123(12):2871-9. (PMID: 18814240)
      Histopathology. 2010 Oct;57(4):646-8. (PMID: 20955392)
      Ann Anat. 2011 Feb 20;193(1):43-55. (PMID: 21145716)
      Chin J Cancer. 2011 Jun;30(6):400-6. (PMID: 21627862)
      Arch Gynecol Obstet. 2012 Jul;286(1):173-8. (PMID: 22274645)
      Int J Gynecol Pathol. 2012 Mar;31(2):151-159. (PMID: 22317873)
      Am J Clin Pathol. 2012 Nov;138(5):678-84. (PMID: 23086768)
      Int J Gynecol Pathol. 2015 Jan;34(1):40-6. (PMID: 25473752)
      Pathol Res Pract. 2016 May;212(5):450-5. (PMID: 26972419)
      Cancer. 1985 Jul 15;56(2):403-12. (PMID: 4005805)
      Science. 1984 Nov 30;226(4678):1097-9. (PMID: 6093263)
      Am J Pathol. 1995 Feb;146(2):501-8. (PMID: 7856759)
      EMBO J. 1995 Nov 15;14(22):5638-45. (PMID: 8521821)
      J Clin Invest. 1996 Jul 15;98(2):451-9. (PMID: 8755656)
      Cell Growth Differ. 1996 Mar;7(3):405-12. (PMID: 8838870)
      Mod Pathol. 1998 Feb;11(2):155-68. (PMID: 9504686)
    • Grant Information:
      GO KAEK 2016/194 Kocaeli Üniversitesi (TR)
    • Contributed Indexing:
      Keywords: BCL-2; Endometrial hyperplasia; Endometrial intraepithelial neoplasia; Immunohistochemistry; PAX2; Uterus
    • Accession Number:
      0 (BCL2 protein, human)
      0 (Biomarkers, Tumor)
      0 (PAX2 Transcription Factor)
      0 (PAX2 protein, human)
      0 (Proto-Oncogene Proteins c-bcl-2)
    • Publication Date:
      Date Created: 20171223 Date Completed: 20190610 Latest Revision: 20200225
    • Publication Date:
      20221213
    • Accession Number:
      10.1007/s12253-017-0378-0
    • Accession Number:
      29270778